Cargando…

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)

BACKGROUND: Omadacycline (OMC) is approved for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Real-world data on the use of OMC are limited. We present a multicenter observational review of OMC outpatient use in Infectious Disease POIC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Anglen, Lucinda J, Schroeder, Claudia P, Couch, Kimberly A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752220/ http://dx.doi.org/10.1093/ofid/ofac492.857

Ejemplares similares

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
por: Prokesch, Richard C, et al.
Publicado: (2019)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2018)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

755 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs Traditional Home Health Care (HHC)
por: Prokesch, Richard C., et al.
Publicado: (2014)

763 Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics (IVABs)
por: Alvarado, Fernando S., et al.
Publicado: (2014)

313. Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
por: Metzger, Brian S, et al.
Publicado: (2018)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

598. A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
por: Hengel, Richard L, et al.
Publicado: (2021)

2081. Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
por: Luu, Quyen, et al.
Publicado: (2019)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
por: Adams, John S, et al.
Publicado: (2019)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software
por: Schroeder, Claudia P, et al.
Publicado: (2022)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2021)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
por: Van Anglen, Lucinda J, et al.
Publicado: (2017)

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics
por: Metzger, Brian S, et al.
Publicado: (2020)

1895. Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
por: Shen, Edmund, et al.
Publicado: (2023)

2903. Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
por: Crotty, Matthew P, et al.
Publicado: (2023)

1208. Omadacycline In Vitro Activity Against Bacillus Anthracis
por: Serio, Alisa W, et al.
Publicado: (2021)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile
por: Skinner, Andrew M, et al.
Publicado: (2022)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

210. Vancomycin Infusion Frequency and Intensity: Analysis of Real-World Data Generated from Automated Infusion Devices
por: Yamaga, Cynthia, et al.
Publicado: (2020)

590. Vancomycin Infusion: Algorithmic Analysis of Unstructured Real-World Data Captured from Automated Infusion Devices
por: Bostick, David L, et al.
Publicado: (2020)

2577. Comparing Omadacycline with Existing Antibiotics in the treatment of Acute Bacterial Infections: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2023)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lq8elos1fmggg6c9ek60hgnkc3